Hepatic Arterial Embolization with Doxorubicin-Loaded Superabsorbent Polymer Microspheres in a Rabbit Liver Tumor Model

Journal Article · Sat Oct 15 00:00:00 EDT 2011 · Cardiovascular and Interventional Radiology

DOI:https://doi.org/10.1007/S00270-011-0154-6· OSTI ID:21608592

Gupta, Sanjay; Wright, Kenneth C ^[1]; Ensor, Joe ^[2]; Van Pelt, Carolyn S ^[3]; Dixon, Katherine A; Kundra, Vikas ^[1]

---

1. University of Texas M. D. Anderson Cancer Center, Department of Diagnostic Radiology (United States)
2. University of Texas M. D. Anderson Cancer Center, Department of Biostatistics (United States)
3. University of Texas M. D. Anderson Cancer Center, Department of Veterinary Medicine and Surgery (United States)

Objectives: The pharmacokinetic profile after hepatic arterial embolization with superabsorbent microspheres (QuadraSpheres) loaded with doxorubicin was studied. Methods: Rabbits with hepatic VX2 tumors were treated with intra-arterial administration of QuadraSpheres loaded with doxorubicin, or transarterial chemoembolization (TACE) using doxorubicin, Lipiodol and Embospheres, or hepatic arterial infusion (HAI) of doxorubicin. Tumor specimens were evaluated by fluorescence microscopy, and plasma and tumor concentrations of doxorubicin were measured. Results: The peak plasma concentration of doxorubicin was lower in the QuadraSphere group (309.9 ng/ml) than in the HAI (673.4 ng/ml) or TACE (360.5 ng/ml) groups, suggesting higher tumor retention in the QuadraSphere group. Intratumoral doxorubicin levels declined to negligible levels at 1 and 3 days after treatment, respectively, in the HAI and TACE groups. In the QuadraSphere groups, intratumoral doxorubicin level declined after day 1, but was still detectable at 14 days after treatment and was higher than that in the other groups at 1, 3, and 7 days. Intratumoral doxorubicin fluorescence was detected at all time points in the QuadraSphere group, but only at 1 day after treatment in the TACE group. Conclusions: Hepatic arterial administration of doxorubicin-loaded QuadraSpheres enables the sustained release of doxorubicin to hepatic tumors.

• OSTI ID: 21608592
• Journal Information: Cardiovascular and Interventional Radiology, Vol. 34, Issue 5; Other Information: DOI: 10.1007/s00270-011-0154-6; Copyright (c) 2011 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
62 RADIOLOGY AND NUCLEAR MEDICINE
DOXORUBICIN
FLUORESCENCE
INFUSION
LIPIODOL
LIVER
MICROSCOPY
MICROSPHERES
NEOPLASMS
PEAKS
PLASMA
POLYMERS
RABBITS
RETENTION
ANIMALS
ANTIBIOTICS
ANTI-INFECTIVE AGENTS
ANTINEOPLASTIC DRUGS
BODY
CONTRAST MEDIA
DIGESTIVE SYSTEM
DISEASES
DRUGS
EMISSION
GLANDS
INTAKE
LUMINESCENCE
MAMMALS
OILS
ORGANIC COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC IODINE COMPOUNDS
ORGANS
OTHER ORGANIC COMPOUNDS
PHOTON EMISSION
VERTEBRATES